Biosensors   

Is Biosensors a good buy?

Bengster i agree with you EXCEPT  the point that the pricing of their shares when they took over JwMs was a blunder. On the Contrary,.to me this is a  brilliant strategic move and eventually will make Biosensors a more attractive take over target . The dilution  is a necessay move which in the long run will prove Biosensors had the foresight. .

 

thks. i will put it in one of my watchlist

 

All those who don't know Conor was losing US$50m year after year raise your hand. All those who don't know Conor was suffering from worldwide litigations from Angiotech for copyright infringement which Conor lost for most of the cases raise your hand. All those who don't know JNJ bought Conor for US$1.4B raise your hand. All those who still don't know Conor's Costar DES totally cannot work raise your hand. Glad that no one raised their hands here. BIG is the last and best PROPRIETARY and PATENTED stent technology company for takeover target. This is a rough guide how much BIG can worth during takeover.  

I feel BIG really made a  silly blunder to price their shares so cheap when they takeover JWMS. The market later thought that BIG feels that their shares are actually worth only so much. However, I can see BIG was actually quite desperate to close the deal quick before any more change of mind by the JW Chinamen shareholders. BIG bought JW at 15 times 2006 PE, 8 times 2007 PE, 5 times 2008 forward PE. When BIG spin off JW, the market will eventually price JW at 30 times 2008 PE, means BIG's JW shares are actually worth 6 times (PE of 30 divide by 5). Despite of BIG's pricing blunder during this acquisition, im very pleased with this acquisition. JW will eventually bring big fortune to BIG.

I feel BIG's share price will not behave so volatile after CE. Look at JW, in first 9 months after approval, JW made US$8.5m in 2006 and will make US$16m for 2007 in China market alone. See how fast money can start rolling in after approval?    

 

all those who don't know that biosensors is a loss-making company, pls raise your hands!

 

but tis loss-making company is able to price itself at 63c/share when it bought over JWMS. not bad.

either JWMS pple are not very bright in accepting such a price. or perhaps *gasp* BIG is in fact not worthless after all!

AND, despite being loss-making, its lowest ever share price  was only 56c! wow!

 

wat if it actually starts to make $? maybe if starts to make $, the price may go even lower..maybe can buy BIG at 20c! mkt is crazy after all.

if it wants to sell-down a stock, it will sell-down the stock. no excuses needed.

 

I think before this company can turn in profit, it will be bought up already. 

 

				Net Earnings	($m)	Earnings Per	Share(cts)	Net Earning
Company	Date	Period	Currency	This Year	Last Year	This Year	Last Year	Gain %
Biosensors	20071112	Q2	US	(10.989)	(9.171)	(1.190)	(1.010)	(19.823)
Biosensors	20070813	Q1	US	7.951	(6.701)	0.870	(0.740)	218.654
Biosensors	20070525	Preliminary	US	(36.293)	(22.468)	(3.990)	(2.610)	(61.532)

 

Mr Investor, you are indeed very well read. Always have my respect for your unbiased views. You give forumers here very clear explanations on details of how Xtent's system really works. Xtent and Devax offers specialised delivery system previously unmet by conventional single lesion DES delivery system. They have good foresight to choose the right partner because BIG was still very small and not so proven back then. Now, BIG's stent drug and technology proven to be the best so i would say they really bet on the right horse!

As for OrbusNeich's genous bio-engineered stent, they didn't seem to make an impact in the stent industry despite having their CE approved back in 2005. At 6 months results, Genous TLR is 5.3% VS Taxus' 4.3%. TVF  for Genous is 8.4% VS 5.4%. Late-loss is 0.48mm which is BMS standard. There were also cases of thrombosis cases which they claim can be eliminated with their EPC coated stents. Now compared the RCT results for Biomatrix for 9 months results (plus 3 more months)

  http://www.allencaron.com/clients/biosensors/releases/102506a.pdf

Even at 6 months Genous cannot match with Biomatrix's 9 months results. Which stent is better is quite clear from here since both are doing similar small scale RCT against Taxus Express.

Biomatrix results are really hard to beat even 5 years later when newer stent come out. No one would dare to do RCT against Biomatrix even 5 years later. The newer DESs know there is a high chance they would not be able to show non-inferiority against Biomatrix and who rather be save and do it against the proven worst DES Taxus.   

 

I hv downloaded half of my BS, 25000 shares last Mon at a lost of few K. Don't hope him anymore at this moment. Leave the market, soonest possible. Regards.

 

 

I wonder what are the terms of Biosensors' licensing agreements with Terumo, Xtent, Devax , etc?  If it is recurring on an annual basis, it could be worth a fortune.

My understanding (I stand corrected) is that the licensees - while not in the league of the likes of J & J - are not small boys either.   It is therefore a testatment to Biosensors that their licensees think their technology is good enough to use.

 

 

I am personally very impressed with Xtent's technology, and it is to Biosensor's good fortune, that they are using Biosensor's technology.

Briefly, Xtent allows doctors to use stents that are up to 60 cm long, whereas current commercial stent length are only 30-35 cm long. Further more, their technnology allows doctors to determine the exact length of stent needed, in situ (that means while the stent is in the patient's body), and then crimp it immediately - thus avoiding a major problem, currently, call 'geographical miss', where the stents inserted may be too short, but it is too late for the doctor to do anything about it - thus not optimising the treatment.

Also, currently, doctors may have to insert 2 stents to make up for the short length, and these stents often overlap, creating uneveness in the jointed area - giving more problems later.

The technology also allows the doctor to use the same stent, and treat, multiple lesions, as well as multi-vessels, with a single insertion of the carthetar, whereas, currently commercial stent does not allow you to do that - you have to withdraw the carthetar each time you treat a new lesion or a different vessel - creating more complexity, more time, more messiness, etc.

Currently, with their clinical trials, they have probably treated the longest lesion on a patient, ever treated before (approx 60 cm), as well as they are able to also treat very small vessels.

I personally think that if J & J can offer US$1.4 billion for Conners, then Xtent should be worth   more. And it is to Biosensor's benefit, when their technology is commercialised.

This is not an inducement to buy Xtent - Just expressing a personal opinion, with my superficial knowledge of the stent industry - Investors should do their own homework.

 

 

Extracted from CNNMoney dated today.  Note:  Xtent is using Biosensors' propreitory drug eluting stent technology under a license agreeement.

 

MENLO PARK, Calif., Nov. 15 /PRNewswire-FirstCall/ -- XTENT, Inc. today announced that it will present at three upcoming investor conferences. The presentation details are as follows:

 

     Piper Jaffray 19th Annual Health Care Conference
     Tuesday, November 27 at 8:30 a.m. ET
     The Pierre New York, New York City
     Presentation by Greg Casciaro, President and Chief Executive Officer
     A live audio webcast of the presentation will be available online via the
     Investor Relations portion of XTENT's website at
     http://investor.xtentinc.com/events.cfm.


     Lazard Capital Markets Fourth Annual Healthcare Conference
     Wednesday, November 28 at 11:00 a.m. ET
     The New York Palace Hotel, New York City
     Presentation by Tim Kahlenberg, Chief Financial Officer


     Bank of Montreal Focus on Healthcare Conference
     Tuesday, December 4 at 9:00 a.m. ET
     Millennium Broadway Hotel, New York City
     Presentation by Tim Kahlenberg
     The webcast will be available at
     http://www.bmocm.com/conferences/2007healthcare/.

 

About XTENT

 

 

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT Custom NX DES Systems have not been approved for sale by any regulatory authority.

Information about XTENT is available at our website at http://www.xtentinc.com

 

anybody knows this stent call genous? recommended by doctor in singapore and the drug is epc capture. what is the diff?

 

How about like that, if you guys have questions about BIG, i will try to give you some answers. I cannot predict prices and don't know what direction the share price will go tomorrow. There are many people here who have done research in BIG also and their contributions are very valuable too. We learn from each other here.

 

I got to attend meeting mah. Last nite i made some posts already. When i talk, people may think i trying to ask people to buy so i can sell my shares. When i don't talk people think i have no confidence in the share price. I kena slander in a lot of forum threads so a bit sianz. My name has always been used when people lost money.

Sinostar? See No Star liao. I thought a couple of months back someone said sell BIG and invest in jade/sinostar in all the forum threads in singapore? Price go up and down so no one to blame. I didn't slander anyone of evil or hai si ren.   

 

Biosensor only drop 1c.  already very good.  if you see sinostar,  since the high of 98c drop until now.  Almost half gone.

 

haiz.... when he talk ppl say him...when he dont talk we get worry ......

 now we miss him right .... well.. i think we in good hands....

 

Haha.. poppy.. dun worry lah.. nothing to report mah.. today almost all counters dived south.. wat's there to report rite.. hehe Cool.... and Cheers

 

When our Mr Biosensor - Bengster don't talk....I am very concern.......

 

covered half at 0.76, ok profit for 1 day trade.

 

This one's a roller coaster today. Notice how fast the price moves. With good entry/exit pts, most likely can short/contra several times today